Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Anumantha Kanthasamy
Iowa State University, Department: Veterinary Sciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
PK Biosciences Corporation
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
PK Biosciences Corp. conducts research and development of therapeutic and diagnostic strategies for neurological diseases including Parkinsons Disease and the NIH-funded project is entitled, "Oxidative Stress Induced Compensatory Protective Mechanisms in PD." The FCOI determination is based on a determination that PK Biosciences Corp. could be perceived as benefiting from the NIH project.
Oxidative Stress Induced Compensatory Protective Mechanisms in PD
Parkinson's disease (PD) is a major neurodegenerative disorder affecting over a million Americans with an associated annual cost of several billion dollars. Current treatment approaches available for PD are symptomatic and fail to prevent the progression of the neurodegenerative process. The present drugs are limited in their effectiveness to either slow or stop the progressive neurodegenerative processes in PD, largely due to the lack of mechanistic insights into the selective dopaminergic degenerative process. We propose to characterize a previously unexplored oxidative signaling pathway in nigral dopaminergic degeneration, and this signaling pathway could provide a novel target for the development of an effective therapeutic agent.
Filed on March 27, 2013.
Tell us what you know about Anumantha Kanthasamy's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Anumantha Kanthasamy filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Anumantha Kanthasamy | Iowa State University | Conflict of Interest | PK Biosciences Corp. | Value cannot be readily determined |
| Anumantha Kanthasamy | Iowa State University | Conflict of Interest | PK Biosciences Corp | Value cannot be readily determined |
| Anumantha Kanthasamy | Iowa State University | Conflict of Interest | PK Biosciences Corporation | Value cannot be readily determined |
| Anumantha Kanthasamy | Iowa State University | Conflict of Interest | PK Biosciences Corporation | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.